The Digestive Diseases and Microbiota group is interested in understanding the role of these microorganisms (bacteria among others) living in the intestine and how alterations to their proportions affect human health and disease. We are a multidisciplinary team with basic basic and clinic researchers. To respond to our research topics we are conducting clinical studies in humans and independent culture techniques focused on DNA sequencing using PCR techniques, and specifically, the 16S rRNA gene of microorganisms present in tissue samples, saliva and / or faeces from patients with different pathologies. These tools allow us to address a whole series of biological issues from a descriptive and functional perspective with the background of exploring the role of intestinal microbiota as an activating agent and as a diagnostic and prognostic tool in the field of different diseases: Crohn's disease and ulcerative colitis, colon cancer, irritable bowel syndrome, celiac disease, chronic pancreatitis, fatty liver, rheumatoid arthritis, colon, and pancreas cancer.
Our main line of research is the study of microbiota in digestive diseases (inflammatory intestinal disease, colorectal cancer, chronic pancreatitis, pancreatic cancer, hepatic steatosis, hepatocarcinoma, etc.), with the intention of finding microbiological markers that can be used as prognosis, diagnosis and monitoring tools and support for these digestive pathologies.
Our group will focus its efforts around three very clear goals:
Work on a broad-ranging study in the correlation of indices developed during the previous period (MC and CRC) with clinical determinants of intestinal diseases for risk determination, pre-diagnosis screening and intestinal disease monitoring.
These tools for monitoring the state of the intestinal microbiota will allow delve deeper into the concept of mucous healing, a condition that involves the reversion of a dysbiosis situation to basal or normal conditions.
Identify genetic elements involved in the pathotype "Adherent-invasive Escherichia coli' and molecular tool design for its detection in patients with Crohn's disease
Explore the establishment of a new line in the hepatopancreatic field dedicated to exploring the possible microbiological markers in faeces from patients with chronic pancreatitis that progress to pancreatic cancer and patients with hepatic steatosis who develop hepatocarcinoma. In fact this year (2015), Dr. Silvia Virolés has begun her thesis focusing on the study of the microbiota during the different phases of hepatic steatosis until the onset of hepatocarcinoma, with the aim of finding a microbiological marker linked to the prognosis for this disease.
Unraveling the influence of gut microbiota and derived metabolites on major depression: A cross-sectional neuroimaging-metabolomics study based on knowledge transfer from irritable bowel syndrome (IBS) and a porcine model: MOODGUT
Codi oficial: 409/C/2022 Start date:13/01/2023 Data fi: 13/01/2028 Investigador/a principal: JESÚS LIBRADO GARCÍA GIL, JOSEP ORIOL MIQUEL CUSACHS Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 86,625 €Analysis of microbiota patterns linked to pancreatic cancer and their role in host inflammation, oxidative stress, and immune status.
Codi oficial: La Marató 201912-31 Start date:30/09/2020 Data fi: 31/01/2024 Investigador/a principal: XAVIER ALDEGUER MANTE Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 199,812.50 €Ajuts per donar suport a les activitats dels grups de recerca de Catalunya (SGR-Cat 2021) - Malalties digestives i microbiota
Codi oficial: 2021 SGR 01366 Start date:01/01/2022 Data fi: 31/12/2024 Investigador/a principal: ROBERT CARRERAS TORRES Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER. Ajuda: 0 €Ayuda de personal Miguel Servet
Codi oficial: CP21/00058 Start date:01/01/2022 Data fi: 31/12/2026 Investigador/a principal: ROBERT CARRERAS TORRES Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 202,500 €Towards HCV elimination among immigrant people in the area of Girona: study for the diagnoses of HCV and HBV among people who attend the Emergency Medical Services
Codi oficial: 2022_GIL_JPP Start date:09/02/2023 Data fi: 08/02/2025 Investigador/a principal: JAVIER PAMPLONA PORTERO Organisme finançador: GILEAD SCIENCES, S.L.U Ajuda: 29,809 €López Siles Mireia, García Gil Librado Jesús, Aldeguer Manté Xavier, Martínez Medina Margarita
METHOD FOR THE QUANTIFICATION OF FAECALIBACTERIUM PRAUSNITZII PHYLOGROUP I AND/OR PHYLOGROUP II MEMBERS AND THE USE THEREOF AS BIOMARKERS
Número de publicació: WO2017025617
Data de publicació: 2017-02-16
Serra Pagès Mariona, García-Gil Jesús, Mas De Xaxars Teresa, Aldeguer Xavier
METHOD FOR DIAGNOSING COLORECTAL CANCER FROM A HUMAN FECES SAMPLE BY QUANTITIVE PCR, PRIMERS AND KIT
Número de publicació: WO2015132273
Data de publicació: 2015-09-11
